The Company offers two testing options that aid gastroenterologists in determining pancreatic cancer risk and patient management.
PancraGEN®, a fully integrated reporting of first-line and molecular test results, and PanDNA®, a molecular-only reporting option for physician integration and interpretation of all test results, enable gastroenterologists to determine the risk of patients developing pancreatic cancer using “integrated molecular pathology”, a proprietary and well documented combination assessment of tumor suppressor genes, loss of heterozygosity, imaging, chemistries, and other first line testing.
Integration of molecular and first-line results helps inform the best course of action in patient management—from surgery to active surveillance.
